Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Recruiting3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

recruiting375%
completed125%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_2

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

NCT06124963
recruitingphase_1

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

NCT06117566
recruitingphase_2

A Study of WX390 in Patients With Advanced Solid Tumors

NCT06117540
completedphase_1

A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

NCT06132932

Clinical Trials (4)

Showing 4 of 4 trials
NCT06124963Phase 2

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

Recruiting
NCT06117566Phase 1

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Recruiting
NCT06117540Phase 2

A Study of WX390 in Patients With Advanced Solid Tumors

Recruiting
NCT06132932Phase 1

A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4